Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Oct 1 · below the Ichimoku cloud · RSI 28 (oversold) · MACD below its signal
| 6.45 | 52-week high | +43.33% |
| 5.90 | Previous month high | +31.11% |
| 5.23 | Previous week high | +16.22% |
| 5.05 | R3 (classic) | +12.33% |
| 5.04 | Previous month low | +12.00% |
| 4.93 | R2 (classic) | +9.56% |
| 4.91 | Previous week low | +9.11% |
| 4.80 | Previous day high | +6.78% |
| 4.73 | R1 (classic) | +5.11% |
| 4.61 | Pivot | +2.33% |
| 4.50 | Price now | |
| 4.48 | Previous day low | −0.44% |
| 4.41 | S1 (classic) | −2.11% |
| 4.28 | S2 (classic) | −4.89% |
| 4.08 | S3 (classic) | −9.33% |
| 2.87 | 52-week low | −36.22% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $5.3M | 0.01% | 1.13M | −3.0% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a AVIR trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 17, 2026 | Polsky BruceDirector | — | 29.6K | — |
| Jun 17, 2026 | Lucidi BrunoDirector | — | 29.6K | — |
| Jun 17, 2026 | Murphy Polly ADirector | — | 29.6K | — |
| Jun 17, 2026 | Adams Jerome M. M.D.Director | — | 29.6K | — |
| Jun 17, 2026 | Duncan Barbara GayleDirector | — | 29.6K | — |
| Jun 17, 2026 | Berger Franklin MilanDirector | — | 29.6K | — |
| May 17, 2026 | Murphy Polly ADirector | Purchase at price 4.17 per share. | 6.1K | $25.45K |
| Mar 10, 2026 | Corcoran Andrea JChief Financial Officer | Conversion of Exercise of derivative security at price 1.24 per share. | 60K | $74.40K |
| Feb 2, 2026 | Sommadossi Jean-PierreChief Executive Officer | Conversion of Exercise of derivative security at price 1.24 per share. | 573K | $372.00K |
| Jan 29, 2026 | Foster Wayne CpaOfficer | — | 41.3K | — |
| Jan 29, 2026 | Horga Maria ArantxaOfficer | — | 51.3K | — |
| Jan 29, 2026 | Hammond Janet MjOfficer | — | 58K | — |
| Jan 29, 2026 | Vavricka JohnOfficer | — | 42.1K | — |
| Jan 29, 2026 | Corcoran Andrea JOfficer | — | 54.9K | — |
| Jun 19, 2025 | Polsky BruceDirector | — | 29.6K | — |
| Jun 19, 2025 | Lucidi BrunoDirector | — | 29.6K | — |
| Jun 19, 2025 | Murphy Polly ADirector | — | 29.6K | — |
| Jun 19, 2025 | Adams Jerome M. M.D.Director | — | 29.6K | — |
| Jun 19, 2025 | Duncan Barbara GayleDirector | — | 29.6K | — |
| Jun 19, 2025 | Berger Franklin MilanDirector | — | 29.6K | — |
TimeframesUp on the monthly, down on the hourly and daily, mixed on the weekly.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
pulling back under the 21 EMA
over a rising 21 EMA, 21 over 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 18.8 | 10.4 | 15.0 | 2.4 | -15.2 | -0.4 | 1.1 | 13.8 | -2.6 | -13.6 | +26.1% | ||
| 2025 | -8.7 | -1.0 | -1.3 | -1.3 | 0.7 | 21.2 | 1.1 | -7.7 | -13.7 | 12.1 | -4.6 | 15.2 | +6.6% |
| 2024 | 36.4 | 3.6 | -6.3 | -8.4 | -0.8 | -9.8 | 15.4 | 0.8 | -13.0 | -3.3 | 5.6 | -2.0 | +9.8% |
| 2023 | -3.7 | -23.5 | -5.4 | -2.4 | 22.0 | -6.3 | -8.3 | -2.0 | -10.7 | 8.3 | -8.0 | 2.0 | −36.6% |
| 2022 | -20.1 | -11.2 | 13.9 | -18.7 | 34.2 | -9.9 | 15.5 | -8.5 | -24.1 | 5.4 | -21.8 | 2.6 | −46.2% |
| 2021 | 74.7 | 3.2 | -18.1 | -60.0 | -17.4 | 5.2 | 16.6 | 18.7 | 18.0 | -66.8 | -30.5 | 10.5 | −78.6% |
| 2020 | 9.8 | 25.4 | +37.7% |
Buy / hold / sell counts
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.